SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 413 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,171,999 | +2.3% | 92,163 | -3.4% | 0.21% | +9.5% |
| Q2 2023 | $10,925,093 | -18.7% | 95,399 | -2.2% | 0.19% | -30.9% |
| Q1 2023 | $13,444,627 | +4.4% | 97,545 | -1.9% | 0.28% | -2.1% |
| Q4 2022 | $12,883,362 | +14.7% | 99,424 | -2.2% | 0.28% | +8.9% |
| Q3 2022 | $11,232,000 | +38.5% | 101,614 | -6.1% | 0.26% | +45.8% |
| Q2 2022 | $8,108,000 | -4.4% | 108,161 | -0.3% | 0.18% | +18.0% |
| Q1 2022 | $8,477,000 | -14.9% | 108,508 | -1.9% | 0.15% | -12.8% |
| Q4 2021 | $9,958,000 | -2.1% | 110,588 | +0.5% | 0.17% | -8.5% |
| Q3 2021 | $10,175,000 | +14.8% | 110,026 | -3.5% | 0.19% | +17.5% |
| Q2 2021 | $8,861,000 | +7.6% | 113,986 | +3.2% | 0.16% | +1.9% |
| Q1 2021 | $8,235,000 | -32.3% | 110,496 | +54.8% | 0.16% | -36.4% |
| Q4 2020 | $12,170,000 | +13.6% | 71,380 | -6.4% | 0.25% | -2.8% |
| Q3 2020 | $10,710,000 | -16.2% | 76,266 | -4.3% | 0.25% | -19.4% |
| Q2 2020 | $12,774,000 | +60.7% | 79,666 | -1.9% | 0.32% | +30.7% |
| Q1 2020 | $7,947,000 | -35.0% | 81,236 | -14.3% | 0.24% | -10.1% |
| Q4 2019 | $12,229,000 | +56.5% | 94,771 | -8.7% | 0.27% | +45.7% |
| Q3 2019 | $7,816,000 | -52.7% | 103,776 | -4.5% | 0.18% | -52.5% |
| Q2 2019 | $16,508,000 | -29.1% | 108,641 | -44.4% | 0.39% | -26.4% |
| Q1 2019 | $23,291,000 | +6.1% | 195,407 | -2.8% | 0.53% | -7.2% |
| Q4 2018 | $21,947,000 | -35.5% | 201,112 | -4.6% | 0.57% | -19.7% |
| Q3 2018 | $34,043,000 | +4.7% | 210,781 | -14.3% | 0.71% | +5.5% |
| Q2 2018 | $32,525,000 | +51.3% | 246,066 | -15.2% | 0.67% | +58.9% |
| Q1 2018 | $21,495,000 | +27.5% | 290,121 | -4.3% | 0.42% | +29.9% |
| Q4 2017 | $16,859,000 | +12.1% | 303,006 | -8.6% | 0.32% | +17.0% |
| Q3 2017 | $15,043,000 | +30.5% | 331,641 | -3.0% | 0.28% | +25.3% |
| Q2 2017 | $11,523,000 | +7.6% | 341,816 | -5.5% | 0.22% | +8.3% |
| Q1 2017 | $10,706,000 | – | 361,701 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |